Last updated: February 22, 2026
What is NDC 00469-2860?
NDC 00469-2860 corresponds to Ruxolitinib, a Janus kinase (JAK) inhibitor marketed under the brand name Jakafi. Approved by the FDA in 2011, it is indicated for treating myelofibrosis, polycythemia vera, and graft-versus-host disease.
Market Size and Dynamics
Current Market Size
- Global market for JAK inhibitors, including ruxolitinib, was estimated at $4.5 billion in 2022[1].
- Ruxolitinib accounts for approximately 70% of this market, translating to around $3.15 billion annually[2].
- The U.S. accounts for approximately 60% of global sales, valued at $2.7 billion.
Key Market Drivers
- Increasing prevalence of myeloproliferative neoplasms.
- Expanded indications for graft-versus-host disease following recent approvals.
- Growing adoption in hematology-oncology practice.
- Pipeline developments for additional indications.
Competitive Landscape
| Drug |
Company |
Year Approved |
Indications |
Market Share (2022) |
Price (per 60 mg tablet) |
| Ruxolitinib (Jakafi) |
Incyte |
2011 |
Myelofibrosis, PV, GVHD |
70% |
~$73 |
| Fedratinib |
Celgene (recently BMS) |
2019 |
Myelofibrosis |
10% |
~$65 |
| Itacitinib |
Novartis (clinical) |
Phase 3 |
GVHD (Awaiting approval) |
2% |
N/A |
| Other JAK inhibitors |
Small / emerging |
Variable |
Experimental/early-stage |
18% |
Varies |
Market Trends & Opportunities
- The demand for ruxolitinib remains robust, driven by its first-mover advantage.
- Expansion into new indications and off-label uses signals future growth.
- Biosimilar and generic entrants are not yet prominent due to patent exclusivity; patent expiry expected around 2026.
Price Projections
Short-Term (Next 2 Years)
- Due to high drug demand and limited competition, prices are likely to sustain around $70–$75 per 60 mg tablet.
- Incremental price increases, approximately 3–5% annually, are typical, driven by inflation and market dynamics.
Medium to Long-Term (Next 5-10 Years)
- Patent expiration anticipated around 2026 could lead to generic entry.
- Generic versions may reduce prices to $35–$50 per 60 mg tablet within 1-2 years post-patent expiry.
- Market share of generics may reach up to 70% within 3 years of entry.
Impact of Biosimilars and Competition
- Biosimilar development is in preliminary stages; approval and market entry could occur by 2028.
- The entrance of biosimilars could cut prices by 30–50%, depending on market uptake.
Regulatory & Policy Factors
- FDA policies favor drug innovation and delayed entry of generics.
- Patent challenges or litigation could extend exclusivity.
- State and federal reimbursement policies influence pricing and market access.
Summary
| Parameter |
Current Estimate |
Future Projection (Next 2-3 Years) |
Future Projection (Post-2026) |
| Global Market Size |
~$4.5 billion |
Stable or slightly growing |
Decreases due to generics |
| U.S. Market Share |
~$2.7 billion |
Remains dominant |
Declines with generics |
| Tablet Price (60 mg) |
~$73 |
~$75 |
~$35–$50 (if generics) |
| Patent Expiry |
2026 |
— |
Patent expiration occurs |
Key Takeaways
- Ruxolitinib (NDC 00469-2860) maintains a dominant market position with revenues around $3 billion annually.
- Pricing remains stable due to limited near-term competition but is susceptible to decline following patent expiry.
- The market outlook depends heavily on the timing of generic and biosimilar entries, estimated around 2026–2028.
- Expanded indications and pipeline advancements could sustain growth pre-patent expiry.
- Regulatory landscape and reimbursement policies are critical in shaping long-term market and pricing strategies.
FAQs
Q1: How soon could generic versions of ruxolitinib enter the market?
A1: Patent expiry is expected around 2026, with generics potentially entering within 1-2 years afterward.
Q2: What factors could influence the price of ruxolitinib?
A2: Patent protection, competitive biosimilar/generic entry, regulatory changes, and payer policies.
Q3: Are there off-label uses affecting the market?
A3: Some off-label use exists, but primary revenue derives from approved indications such as myelofibrosis and PV.
Q4: How does the development pipeline impact future prices?
A4: New indications or formulations could sustain or increase prices until generics impact the market.
Q5: What is the potential for biosimilars?
A5: Biosimilar development is in early stages, with potential approval around 2028, possibly reducing prices significantly.
References
[1] MarketWatch. (2022). Global Janus kinase inhibitors market report.
[2] Incyte. (2022). Ruxolitinib sales data and quarterly earnings reports.
